| Original language | English |
|---|---|
| Publication status | Published - 2018 |
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: A systematic review and cost-effectiveness analysis
Research output: Book/Report › Commissioned report